• Founder(s): Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier 
  • Established: March 2016
  • CEO(s): Sebastian Meier-Ewert
  • Employees: >20
  • Financial Data: Privately funded
  • Website:


This startup is developing next-generation cancer immunotherapies targeting novel immune evasion pathways.

iOmx focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the company has already identified a number of novel targets and analyzed their mode of action.

Their location advantages include a critical mass of biotech companies, life science institutions and service providers in addition to a high quality of life.